CCR5 inhibitors: emergence, success, and challenges

  title={CCR5 inhibitors: emergence, success, and challenges},
  author={K. Maeda and D. Das and Hirotomo Nakata and H. Mitsuya},
  journal={Expert Opinion on Emerging Drugs},
  pages={135 - 145}
  • K. Maeda, D. Das, +1 author H. Mitsuya
  • Published 2012
  • Medicine
  • Expert Opinion on Emerging Drugs
  • Introduction: The discovery of CC-chemokine receptor 5 (CCR5) as a human immunodeficiency virus type 1 (HIV-1) coreceptor opened a new avenue to exploit CCR5 as a potential target for the intervention of HIV-1's cellular entry. Areas covered: Various small-molecule CCR5 inhibitors were identified in the last decade; however, maraviroc (MVC) is the only CCR5 inhibitor currently used in the clinic. Concerns and challenges that exist for wider clinical use of CCR5 inhibitors are discussed. Expert… CONTINUE READING
    31 Citations

    Topics from this paper.

    Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore‐based virtual screening approach
    • 1
    • Highly Influenced
    Synergistic Combinations of the CCR5 Inhibitor VCH-286 with Other Classes of HIV-1 Inhibitors
    • 8
    • PDF
    Insights into the Mechanism of Inhibition of CXCR4: Identification of Piperidinylethanamine Analogs as Anti-HIV-1 Inhibitors
    • 21
    • PDF
    Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies
    • 3
    • PDF
    A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
    • R. Manfredi, L. Calza, +7 authors P. Viale
    • Medicine
    • Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive
    • 2015
    • 4
    • Highly Influenced
    • PDF
    TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus
    • 15
    The CCL5/CCR5 Axis in Cancer Progression
    • 3
    • PDF


    Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
    • 33
    Clinical Utility of Maraviroc
    • 25
    HIV-1 entry inhibitors: an overview
    • 142
    Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists
    • 173
    • PDF
    Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry
    • 229
    • PDF
    A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    • M. Baba, O. Nishimura, +9 authors M. Fujino
    • Medicine, Biology
    • Proceedings of the National Academy of Sciences of the United States of America
    • 1999
    • 746
    • PDF
    Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)*
    • 92
    • PDF